Background Disease-modifying treatment strategies for Alzheimer's disease have led to an
urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup
in the clinic but also to facilitate the development and monitoring of effective disease-…

Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-…

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer’s disease (AD). Recently, we showed that abnormal levels of Aβ42 in cerebrospinal …

The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …

Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) as …

Alzheimer’s disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, …

Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …